UT Health San Antonio and UT Health Houston have granted exclusive global license agreements on two of their biologic therapeutics for spinal cord injury and breast cancer bone metastasis to AlaMab Therapeutics, a subsidiary of CSPC Pharmaceutical Group Ltd.
The San Antonio Chamber announced the license agreements for the first-in-class therapies in a recent press release and called the agreements some of the most financially significant in UT Health San Antonio history.
Also according to the Chamber, AlaMab and CSPC will seek regulatory approval in the U.S. and China as well as other global markets and plans to partner with UT Health San Antonio for pre-clinical investigation and development of the therapeutics.
The original research and discovery of the antibodies was done by UT Health San Antonio professor Ashbel Smith and Jean Jiang, professor of biochemistry and structural biology at UT’s Long School of Medicine.
“Dr. Jiang’s track record of innovative and excellent research has attracted more than $10.2 million to UT Health San Antonio, including nearly $9.2 million from the National Institutes of Health and $925,000 from The Welch Foundation,” the Chamber stated in the announcement.
A 2016 Economic Impact Study by the Chamber, shows the city’s bioscience sector has an approximately $37 billion impact on the local economy.